4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 8,153 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMTGet Free Report) insider Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total transaction of $259,102.34. Following the sale, the insider now owns 1,737 shares of the company’s stock, valued at $55,201.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Scott Bizily also recently made the following trade(s):

  • On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total value of $204,388.32.
  • On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.27, for a total transaction of $54,722.50.
  • On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $57,270.00.
  • On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.67, for a total value of $48,422.50.
  • On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.50, for a total value of $171,710.00.

4D Molecular Therapeutics Trading Down 0.2 %

Shares of FDMT opened at $27.92 on Thursday. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The firm has a 50-day simple moving average of $27.97 and a 200-day simple moving average of $19.16.

4D Molecular Therapeutics (NASDAQ:FDMTGet Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. The company had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. Equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on FDMT shares. BMO Capital Markets lowered their target price on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday. Jefferies Financial Group raised their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $81.00 price objective on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Royal Bank of Canada raised their target price on 4D Molecular Therapeutics from $25.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.60.

View Our Latest Stock Analysis on FDMT

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. RA Capital Management L.P. acquired a new stake in 4D Molecular Therapeutics in the second quarter valued at about $55,466,000. State Street Corp lifted its holdings in shares of 4D Molecular Therapeutics by 65.3% in the 1st quarter. State Street Corp now owns 2,042,189 shares of the company’s stock valued at $35,105,000 after buying an additional 807,031 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock valued at $16,539,000 after buying an additional 658,069 shares in the last quarter. BlackRock Inc. grew its holdings in 4D Molecular Therapeutics by 14.3% during the second quarter. BlackRock Inc. now owns 2,914,430 shares of the company’s stock worth $52,664,000 after acquiring an additional 363,695 shares during the period. Finally, Great Point Partners LLC acquired a new position in 4D Molecular Therapeutics during the second quarter worth $6,324,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Recommended Stories

Insider Buying and Selling by Quarter for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.